pan-mutant-selective pi3k-alpha inhibitor rly-5836
Generic: Pan-mutant-selective PI3K-alpha Inhibitor RLY-5836
pan-mutant-selective pi3k-alpha inhibitor rly-5836: 1 clinical trial tracked.
pan-mutant-selective pi3k-alpha inhibitor rly-5836 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pan-mutant-selective pi3k-alpha inhibitor rly-5836, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors
Primary endpoint: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of RLY-5836
Interventionalopen41 enrolledStarted 2023-03Completion 2025-047 sites · United StatesRelay Therapeutics, Inc.